The magnitude of the anabolic bone response to MS2 was similar to increments in bone mass in mice treated with PTH analogues and RANKL blocking antibodies that were developed to treat osteoporosis.26 However, this response required PC1 and Wwtr1 co-dependent signaling, since the administration of MS2 had no effects on bone formation in double Pkd1/Wwtr1Oc-cKO null mice. The gene discussed is WWTR1; the disease is osteoporosis.